Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 5.64
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.
Company Valuation
From both historical and forecast perspectives, the stock is moderately underpriced compared to similar stocks.
Data is available to registered users only
Target Price
The average target price of KLRS is 21 and suggests 277% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Data is available to registered users only
Buy
Sell